Prelude is a relatively new a new French startup that focuses on SMS verification; it's announcing new funding from Singular ...

Paris-based SMS verification technology company Prelude has secured $8 million in seed funding led by Singular and Seedcamp. The company, founded in 2022 by Matias Berny and Quentin Le Bras, develops ...

WILMINGTON, DE — Prelude Therapeutics Incorporated (Nasdaq: PRLD), a precision oncology company, has shared its third-quarter ...

Prelude Therapeutics Inc (PRLD)股票已触及新的52周低点，交易价格为1.1美元，该公司正面临充满挑战的市场环境。这一最新价格标志着这家生物制药公司的重大下跌，过去一年其股票价值下降了65%。投资者正密切关注PRLD的表现，因为该公司正在经历一段波动期，并寻求在竞争激烈的生物科技板块重新站稳脚跟。52周低点成为该公司短期前景和潜在战略调整的关键指标。

Presented interim data from the ongoing Phase 1 dose escalation study of PRT3789, its first-in-class IV SMARCA2 degrader, ...

Prelude Therapeutics Inc (NASDAQ:PRLD), a clinical-stage biopharmaceutical company focused on developing precision oncology therapies, finds itself at a critical juncture as it approaches several ...

In a report released today, Peter Lawson from Barclays maintained a Sell rating on Prelude Therapeutics (PRLD – Research Report), with a price target of $1.00. The company’s shares closed yesterday at ...

09, 2024 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD) (“Prelude” or the “Company”), a clinical-stage precision oncology company, today announced the publication of ...

Prelude Therapeutics ( (PRLD) ) has provided an announcement. Prelude Therapeutics announced its third quarter 2024 financial results, ...

Interim data from ongoing trial of PRT3789 showed additional clinical activity at higher doses in patients with non-small ...